key: cord-1003267-qdjy6ppj
authors: Stessel, Björn; Vanvuchelen, Charlotte; Bruckers, Liesbeth; Geebelen, Laurien; Callebaut, Ina; Vandenbrande, Jeroen; Pellens, Ben; van Tornout, Michiel; Ory, Jean-Paul; van Halem, Karlijn; Messiaen, Peter; Herbots, Lieven; Ramaekers, Dirk; Dubois, Jasperina
title: Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
date: 2020-07-22
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.07.038
sha: 3dc7a0446b45bc130abd23e6f67f6f784f930c5a
doc_id: 1003267
cord_uid: qdjy6ppj

INTRODUCTION: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. METHODS: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. RESULTS: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. CONCLUSION: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. REGISTRATION NUMBER: NCT04394000.

The ongoing pandemic of coronavirus disease 2019 in humans is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This coronavirus was first detected in China in December, 2019. This coronavirus was first detected in China in December, 2019. The spectrum of disease severity of this viral infection is wide: from mild upper respiratory tract infection (RTI) in approximately 80%, to severe lower RTI (e.g. with dyspnoea, PaO2/FiO2 of <300 mmHg, or bilateral lung involvement on imaging) in approximately 15% of cases and critical (e.g. with respiratory failure, shock, and/or multiorgan dysfunction) in 5% 1 2 . Hypoxemic respiratory failure due to acute respiratory distress syndrome (ARDS) has been reported as the dominant finding during intensive care unit (ICU) admission and as a major cause of death 3 4 . These clinical features may suggest that SARS-CoV-2 predominantly targets the respiratory tract. Indeed, the majority of the patients with severe COVID-19 initially present with single organ failure (i.e. respiratory insufficiency) 5 .

Consequently, guidelines on the management of critically ill COVID-19 patients cover predominantly strong recommendations for ventilatory support 6 . Therefore, initial supportive therapy at our ICU, JESSA hospital Hasselt, Belgium, focused mainly at respiratory support with (non)-invasive mechanical ventilation with a higher positive end-expiratory pressure (PEEP) strategy. Hasselt is situated in the epicentre of the Belgian outbreak with the highest incidence across the country 7 .

From the first admission to ICU on March 13 th , admissions of critically ill COVID-19 patients to ICU grew exponentially. All patients were treated with routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH according to the current guidelines in critically ill patients 8, 9 . Nevertheless, deep vein thrombosis (DVT) screening using duplex ultrasound of all intubated and mechanically ventilated COVID-19 patients treated at one ward on March 29 th , revealed a prevalence of DVT of more than 65% 10 . These findings suggested that thrombo-embolic phenomenona may be another, at that time less-well known, major cause of death of severe COVID-J o u r n a l P r e -p r o o f 19 infection. This was further substantiated by the observation that elevated D-dimer levels, a marker of endogenous fibrinolysis and detectable in patients with DVT 11 , are a risk factor for inhospital mortality in patients with COVID-19 [12] [13] [14] . Therefore, we implemented an individualised thromboprophylaxis protocol with augmented doses of LMWH on March 31th in order to reduce mortality and improve clinical outcome.

The aim of this study was to evaluate the effect of this intervention on clinical outcome. The main hypothesis was that implementation of this intensified thromboprophylaxis protocol would have reduced mortality and improved clinical outcome in critically ill COVID-19 patients admitted to ICU.

This mono-centric, investigator-initiated, longitudinal, controlled, before-after study is performed at the ICU department of the Jessa Hospital, Hasselt, Belgium. This study is approved by the ethical committee of JESSA Hospital Hasselt, Belgium on May 4th 2020 and registered on clinicaltials.gov (NCT04394000). Written informed consent was waived in light of the urgent need to collect data in the ongoing pandemic.

All adult patients diagnosed with COVID-19 pneumonia and admitted to ICU before April 20th 2020 were included in the study. Laboratory confirmation of COVID-19 was defined as a positive result on polymerase chain reaction (PCR) assays of nasopharyngeal swab samples, in accordance with the World Health Organisation (WHO) protocol 15 . Only laboratory-confirmed patients were included in the analysis. From March 13 th to May 3th 2020, data from 78 consecutive patients admitted to ICU were prospectively entered into a customized database that included demographic data, medical history, clinical symptoms or signs, laboratory results and clinical outcomes. This database was retrospectively reviewed. APACHE II score was assessed at admission to ICU 16 . The Sequential Organ Failure Assessment (SOFA) score 17 and PaO2/FiO 2 (P/F ratio) were evaluated daily.

J o u r n a l P r e -p r o o f All COVID-19 patients were treated according to the COVID-protocol of the JESSA hospital (additional file 1), based on the latest insights on COVID-19 6 .

All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis, i.e. once-daily subcutaneous injection of nadroparin calcium 2850 IU, according to the current guidelines in critically ill patients 8, 9 Intervention Based on the observation of Pellens et al. 10 prophylactic anti-Xa activity of 0,4-0,6 IU/ml was targeted in patients without objectified need for therapeutic anticoagulation (i.e. medical history or presence of DVT on ultrasonography). In patients with need for therapeutic anticoagulation, a therapeutic anti-Xa concentration of 0,5-1,0 IU/ml was targeted (figure 1).

The primary endpoint is one-month mortality. Secondary outcomes include two-week and threeweek mortality, the incidence of VTE, the incidence of acute kidney injury and continuous renal replacement therapy (CRRT), the lowest P/F-ratio and highest SOFA-score during ICU stay, length of stay (LOS) in the ICU and hospital LOS, and highest bilirubin, AST and ALT during ICU stay. All patients were followed for at least 30 days after submission to ICU. Data set was closed at June 2 th 2020.

Acute kidney failure was diagnosed according to the KDIGO clinical practice guidelines 18 . ARDS was diagnosed according to the Berlin Definition 19 . Sepsis and septic shock were defined according to the 2016 Third International Consensus Definition for Sepsis and Septic Shock .

Patients admitted to ICU from March 13 th until March 30 th 2020 treated with low-dose thromboprophylaxis and patients admitted to ICU March 31 th until April 20 th 2020 treated with an intensified thromboprophylaxis protocol were compared in terms of demographic data, medical history and clinical outcomes. Categorical variables are presented as frequency (%) and groups were compared using Fisher's exact test. Continuous variables are presented as median with interquartile range and groups were compared using Wilcoxon rank sum test.

To compare the two groups for one-month mortality, incidence of acute kidney failure, CRRT and VTE, a logistic regression model, with a Firth correction, was implemented. Worst (lowest) P/F ratio and worst (highest) SOFA score, highest bilirubin, highest AST and highest ALT during ICU stay were J o u r n a l P r e -p r o o f compared by means of linear regression model. A naturally logarithmic transformation of these endpoints was used, to obtain normally distributed residuals.

Age, gender, BMI, hypertension and diabetes together with the SOFA and Apache II score at admission to ICU and D-dimer level and white blood cell count at admission to ICU 12,13,20 were incorporated as explanatory (confounding) variables in the logistic and linear regression models to correct for possible differences between the two groups (e.g. the intensified thromboprophylaxis group is younger). The following stepwise strategy was adopted. First, two groups were compared without a correction for patient characteristics and risk factors. Next, models adjusting the comparison were fitted by incorporating one explanatory/confounding variable at a time. Only variables with a p-value ≤ 0.1 were included in the final multiple regression model.

Based on the final multiple regression model, odds ratios (95% confidence interval) for before versus after group were calculated. An odds ratio larger than 1 indicates an increased risk in the before group. For the continuous variables the ratio (95% confidence interval) of the geometric means were obtained, based on the final multiple regression models. A ratio larger than 1 indicates that the geometric mean of the outcome in the before group is higher than in the after group.

A p-value < 0.05 is considered statistically significant and a p-value < 0.1 is considered a statistical tendency. All analyses were conducted with SAS version 9.4.

In total, 78 COVID-19 patients were admitted to the COVID- 19 16 .00) vs after group: 11.00 (9.00, 14.00), p=0.09) and SOFA scores (before group: 3.50 (2.00, 9.00) vs after group: 4.00 (3.00, 5.00), p=0.69) were seen between both groups. Baseline characteristics are presented in table 1.

The primary outcome, i.e. 1 month mortality was 39.13% (18/46) in the before group and 3.85%

(1/26) in the after group (p<0.001).

One-week mortality was 19.57% (9/46) in before group and 3.85% (1/26) in the after group (p=0.08), two-week mortality was 30.43% (14/46) in the before group and 3.85% (1/26) in the after group (p=0.01) and three-week mortality was 36.96% (17/46) in the before group and 3.85% (1/16) in the after group (p=0.01) (figure 2).

The incidence of VTE, the incidence of acute kidney injury and CRRT, the lowest P/F-ratio and highest SOFA-score during ICU stay, LOS ICU and hospital LOS, and highest bilirubin, AST and ALT during ICU stay, stratified per group are shown in table 2.

One patient in the intervention group suffered major haemorrhage after removal of a pleural drain, requiring surgical exploration and transfusion of packed red cells. This patient however was discharged from the ICU one week after the event. Furthermore, no major adverse events were noted.

In the before group, 1 patient received zovirax (2.1%), in the after group 1 patient received remdesivir (3.84%). Almost all patients in the before group (97.8%) received antibiotic treatment while this was 80.8% in the after group. 13 patients in the before group (28.2%) and 6 patients in the after group (23.1%) received corticosteroids during their stay at ICU.

The results of the final 9 multiple regression models are presented in table 3. For 1 month mortality, gender, BMI, hypertension, diabetes, white blood cells, D-dimers, SOFA and Apache II score were not J o u r n a l P r e -p r o o f statistically significant after univariate logistic regression analysis. Therefore, only age was included in the multiple regression analysis . The final logistic regression model for acute kidney failure incorporated gender, SOFA score at admission and hypertension; the model for CRRT included SOFA score at admission, obesity and D-dimers. The model for VTE included D-dimers. The comparison for lowest P/F ratio was corrected for age; the model for highest SOFA score and bilirubin included gender and SOFA score at admission. The final model for AST included the SOFA score at admission as explanatory variable, ALT was corrected for age, gender and diabetes.

In this mono-centric before-after study involving consecutive critically ill COVID patients admitted to the ICU, one-month mortality significantly decreased from 39.13% to 3.85% by applying more aggressive thromboprophylaxis. After correction for group differences, reduction of one-month mortality was statistically significant. The cumulative incidence of VTE was up to 41% in the before group, despite routine thromboprophylaxis with low-dose LMWH. Cumulative incidence of VTE is probably underestimated in the before group since several patients had already died without being screened for VTE.

After implementation of the individualized, more aggressive thromboprophylaxis protocol, incidence of VTE dropped to 15%. After correction for group differences, reduction of cumulative VTE incidence remained statistically significant. After correction for group differences, also the risk of need for CRRT, higher SOFA score and risk of more severe hepatic laboratory abnormalities, were all in favor ICU mortality in the before group of this study is comparable to ICU mortality reported in literature.

ICU mortality in a multicenter cohort of 1591 COVID-19 patients admitted to ICU´s in Lombardy, Italy, was 26% 26 . Mortality in a small case series of 24 COVID-19 patients admitted to ICU in the Seattle region was even 50% 27 .

The high difference in CRRT was in favor of the intervention group and was only attributable to the higher incidence of severe acute kidney injury in the before group. During the whole study period, sufficient CRRT machines were available. The relationship between VTE and AKI is still undetermined.

However, massive pulmonary embolism is found to be a strong predictor of AKI 28 . The underlying mechanism is not well understood but may be explained by occurrence of pulmonary hypertension and right heart failure with subsequent hemodynamic instability and renal hypoperfusion 28 .

Several pathways of action of LMWH have been described that may explain the observed beneficial effects of increased LMWH dosage in this cohort 29 . The anticoagulant effect of LMWH alone may already explain the reduced risk of VTE and associated death, observed in this study 5, 30 . However, LMWH also have potent anti-inflammatory properties as they can decrease the level of inflammatory biomarkers 29, 31 . These properties may be very important in light of the growing evidence that an exuberant immune response, i.e. a cytokine storm, may be responsible for a more severe disease course after COVID-19 rather than viral virulence 32 . Last but not least, LMWH may even decrease viral infectivity of SARS-CoV2 by blocking cellular entrance of this virus 33 since Factor Xa has been shown to facilitate SARS-CoV entry into the host cells 34 .

On April 11th, the Italian Medicines Agency (AIFA) published a document on heparin use in COVID-19 patients, suggesting doses close to therapeutic ones in severe cases, despite the lack of scientific evidence 35 . We believe that this study provides scientific evidence for this thesis.

Guidelines of the American College of Chest Physicians give a grade 2C recommendation of using LMWH over no prophylaxis but doesn't suggest any LMWH dosage in critically ill patients 8 . After observation of a high prevalence of DVT in our critically ill COVID-19 patients, we decided to increase the prophylactic dose of nadroparin to 3800 IU q12h in all patients and to individually tailor LMWH doses close to therapeutic ranges, based on monitoring plasma anti-Xa activity. Up to date there is no clear-cut evidence that anti-Xa measurements reduce mortality neither morbidity 36 . Therefore, recommendations for the management of LMWH therapy state that routine measurements of anti-Xa activity is not necessary 37 . In contrast, Hirsch already in 2004 suggested that screening of anti-Xa activity might be useful in obese patients, as well as in patients with kidney failure 36 . In light of the high incidence of obesity, kidney failure 12 and VTE in critically ill COVID-19 patients, routine measurements of anti-Xa activity should be considered in this patient group.

Our protocol also included routine duplex ultrasonography of the great veins on admission and twice weekly by a radiologist. The current guidelines however state: 'in critically ill patients, we suggest J o u r n a l P r e -p r o o f against routine ultrasound screening for DVT' 8 . Ultrasonography performed by radiologist however has an excellent sensitivity (91-95%) and specificity (98%) for detection of DVT 38 .

This study has several limitations. The quasi experimental study design is associated with a risk of unidentified confounders. This was the only solution since randomization was not possible because of a need for quick intervention. Due to the mono-centric design of this study, the generalizability of these results may be limited. In the course of the pandemic, we also adapted therapy at other domains. For example, national guidelines for admission to ICU became more stringent in order to secure sufficient ICU capacity. This may explain differences between the two groups, such as age. The relatively small size of this study and the sparsity of the data (especially for mortality and CRRT) results in high odds ratios and wide confidence intervals. The possibility to correct for multiple explanatory variables at the same time is also limited for this reason. Finally, the individualised thromboprophylaxis protocol was implemented on March 31 th in all COVID-19 patients admitted to ICU at that time. Therefore, all patients included in the before group who were not discharged from ICU at that time, also received this treatment. This treatment bias however, may have negatively affected differences in outcome.

In conclusion, our results suggest that mortality, cumulative risk of VTE and need for CRRT may be reduced in critically ill COVID-19 patients by implementing a more aggressive thromboprophylaxis protocol containing close to therapeutic LMWH dosing, individually tailored with routine anti-Xa measurements combined with systematically ultrasonography screening for DVT. Therefore, we advocate the adoption of this protocol in an attempt to improve clinical outcome in critically ill COVID-19 patients. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. J o u r n a l P r e -p r o o f All authors were responsible for the writing of the paper and approved the final manuscript.

All authors give consent for publication of the manuscript.

Not applicable. According to this protocol, all patients admitted to our ICU received an IV-infusion with glucose 5% at 60 ml/h as maintenance fluid and stress ulcer prophylaxis with Pantoprazole 40 mg intravenously daily. Prophylactic antibiotic therapy was initiated for 5 days, using Amoxicillin-clavulanic acid 1 g intravenously 4 times a day or Moxifloxacin 400 mg intravenously once daily in case of known allergy to penicillin. The protocol also comprised the administration of hydroxychloroquine orally starting with a loading dose of 400 mg twice on the first day, followed by 200 mg twice a day, for 4 days, with daily monitoring of the QTC-interval by ECG. This therapy was interrupted if the QTC-interval exceeded 500 ms since QTC-interval prolongation is one of the well-known important side-effects of hydroxychloroquine potentially causing severe cardiac arrhythmias.

Ventilatory support was initiated with a high-flow nasal cannula or non-invasive mechanical ventilation as long as the patient was cooperative to this treatment. In case of respiratory fatigue, patients were sedated and intubated and invasive mechanical ventilation was started according to the ARDS-network guidelines that included a protocol based on low-oxygen and high-PEEP. This was based on the first reports that the viral pneumonia caused by SARS-CoV-2 mimicked an ARDS-like pattern 6 . Sedation was performed by a combination of propofol, midazolam and piritramide aiming for the lowest level of sedation by witch the patient would tolerate the mechanical ventilation.

Adjustments were made guided by spO2-levels, which are continuously monitored and arterial blood gasses taken every 4 hours. In case of hypotension due to vasoplegia, norepinephrine was used as

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine

Care for adult non-ICU Covid-19 patients: early experiences from a Belgian tertiary care centre. The Netherlands journal of medicine

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood advances

Prevalence of Deep Venous Thrombosis in Ventilated COVID-19 Patients: A Mono-Center Cross-Sectional Study

Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. The New England journal of medicine

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Laboratory testing for coronavirus disease 2019 ( COVID-19) in suspected human cases. interim guidance

APACHE II: a severity of disease classification system. Critical care medicine

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine

KDIGO clinical practice guidelines for acute kidney injury

Acute respiratory distress syndrome: the Berlin Definition

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. The European respiratory journal

Acute Cor Pulmonale in Critically Ill Patients with Covid-19. The New England journal of medicine

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis research

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive care medicine

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series. The New England journal of medicine

Acute kidney injury in patients with pulmonary embolism: A population-based cohort study

Journal of thrombosis and haemostasis : JTH

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Medical hypotheses

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochemical and biophysical research communications

Where do we stand with antithrombotic prophylaxis in patients with COVID-19? Thrombosis research

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest

What is the accuracy of emergency physicianperformed ultrasonography for deep venous thrombosis?